US safety data show that elinzanetant caused few adverse events and no new liver-related concerns in women, James Simon, MD, explains.
James Simon, MD
Advertisement
Articles by James Simon, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS
2
House Panel Advances Bills to Expand Veterans’ Health Care Access
3
House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden
4
The Oncology Care Model: A Decade of Transformation
5